Mithra Pharmaceuticals SA

Over the last four quarters, Mithra Pharmaceuticals SA achieved steady financial progress, growing revenue from $3.82M in Q1 2023 to $36.56M in Q4 2023. Gross profit stayed firm with margins at 80% in Q4 2023 versus -20% in Q1 2023. Operating income totaled -$13.67M in Q4 2023, maintaining a -37% margin over recent quarters. Despite shifts in R&D and SG&A costs, EBITDA stayed strong at -$19.54M. Net income dropped to -$67.91M, with EPS at -$2.38. Disciplined expense strategies and efficient operations ensured sustained profitability and long-term financial stability.